Search
PROFILE Bootcamp in Entrepreneurial Innovation in Orphan Diseases, October 23-25, 2017, Leuven, Belgium.
Breaking innovations in rare diseases are at the centre of this PROFILE Bootcamp, which brings together junior & senior researchers, clinicians, pharmaceutical industry and policymakers.
Read morePolicy & advocacy
At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
Read moreEHA-TSH Hematology Tutorial
EHA is joining the Turkish Society of Hematology (TSH) to organize the EHA-TSH Hematology Tutorial on T Cell Lymphomas. Date: June 29-30, 2024
Location: Ankara, Türkiye
Format: In-Person
Target audienceHematology fellows from Türkiye.
EHA-SWG Scientific Meeting on Patient-centered Geriatric Hematology - report
Live sessions: October 6-7, 2021
Chairs: Prof R Cordoba (Spain) and Dr V Goede (Germany)
An international group of hematologists, specialist nurses, patient advocates, geriatricians, basic research, and pharma representatives gathered digitally to participate in this meeting.
EHA Lymphoma Group
The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.
Read moreSocial Media Learning
EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.
Read moreEHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!
EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia
Meeting Chairs:
Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…
Hospital pharmacists and regulators lead the way on shortages
EHA welcomes initiatives but calls for more focus on causes
Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.
Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »